TRINITY BIOTECH PLC Annual Report - How They Did This Year

I’m putting together a plain-English guide to help you understand Trinity Biotech’s performance. My goal is to cut through the corporate jargon so you can decide if this company fits your portfolio.

1. What does this company do and how did they perform this year?

Trinity Biotech creates medical tests for hospitals and labs, focusing on infectious diseases, autoimmune testing, and clinical chemistry. They are currently in a high-stakes growth phase. They are modernizing operations and developing new technology, specifically a continuous glucose monitoring (CGM) platform and the Meritas testing system. They are spending heavily on research and facility upgrades today to position themselves for future growth.

2. Financial performance: The reality of losses

The company is currently operating at a loss. In 2025, they reported a loss of $37.4 million, compared to a $31.8 million loss in 2024. They utilized $5.9 million in cash to support business operations this year, up from $4.2 million the previous year. These figures reflect the high operating costs and the capital required to transition their business model.

3. Major wins and challenges

• Wins: They are integrating new acquisitions, such as the EpiCapture technology, to broaden their testing menu and expand their patent portfolio. They also maintain a disciplined approach to cybersecurity to protect sensitive patient data and meet international standards.
• Challenges: The company carries significant debt, including convertible notes, which limits financial flexibility and requires ongoing interest payments. Additionally, they are managing high costs associated with moving facilities, consolidating manufacturing sites, and optimizing inventory levels.

4. Financial health: Walking a tightrope

Trinity maintains enough cash to operate for the next 12 months. Their long-term outlook depends on generating consistent cash flow from sales or securing additional capital. Because they have loans that can be converted into company stock, their debt levels and stock price are closely linked. If the company does not meet growth targets or if the stock price remains low, they may need to issue more shares, which would dilute the ownership percentage of existing shareholders.

5. Key risks

• Market Competition: The diagnostics market is highly competitive. If competitors launch faster or more cost-effective tests, Trinity’s new products—particularly their CGM platform—may face difficulty gaining the necessary market share to justify their development costs.
• Global Instability: Geopolitical conflicts and trade tensions can disrupt supply chains, potentially increasing the cost or difficulty of sourcing materials needed to manufacture their tests.
• Regulatory Hurdles: As a medical company, they rely on ongoing approvals from agencies like the FDA. Delays in clinical trials or manufacturing inspections can stall operations and prevent the commercialization of new products.

6. The Bottom Line

Trinity Biotech is a "show-me" story. They have a clear strategic plan, but they are currently operating at a loss that has increased over the past year. This is a high-risk investment. It is best suited for those who believe in their specific technology and are willing to wait for the company to pay down debt, successfully launch its new product pipeline, and reach profitability.

Investor Tip: Before investing, consider whether you are comfortable with the company's current debt-to-equity structure and if you have the patience to wait for their long-term R&D projects to reach the commercial market.